Rain Therapeutics Inc. (RAIN) Tops Q4 EPS by 126c

Rain Therapeutics Inc. (NASDAQ: RAIN) reported Q4 EPS of $0.70, $1.26 better than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Rain Therapeutics Inc. (RAIN) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst
• Benchmark Reiterates Buy Rating on Marvell (MRVL) Following Earnings